Skip to content
CTSOCytosorbents Corp

Earnings

When Cytosorbents Corp reports, what it reported each quarter, and how the stock took the results.

65 quarters. Jun 30, 2010 to Jun 30, 2026. USD.

Next results · Q3 2026Released

Nov 12, after the close

Thu, Nov 12, 20266 days ago

The results are out. The figures reach the desk with the 10-Q.

Quarter
Q3 2026 · Ended Sep 30, 2026
10-Q window
Nov 4 – 16

Read against Q3 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$9.49M
Revenue, change from a year earlier: Q2 2026 +0.2%, Q1 2026 +1.6%, Q4 2025 +0.9%, Q3 2025 +10.1%
Net income
-$3.17M
Net income, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m, Q3 2025 n/m
EPS
-$0.05
EPS, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m, Q2 2025 n/m

Quarter by quarter

Q2 2026$9.63M+0.2% vs Q2 2025

Latest results

  1. Q2 2026Aug 6, 2026, after the closeThe release0.8%by the close of Aug 11
    Revenue
    $9.63M
    +0.2%
    Net income
    -$4.42M
    N/M
    EPS
    -$0.07
    N/M
  2. Q1 2026May 13, 2026, after the closeThe release6.0%by the close of May 14
    Revenue
    $8.86M
    +1.6%
    Net income
    -$5.13M
    N/M
    EPS
    -$0.08
    N/M
  3. Q4 2025Mar 25, 2026, after the closeThe release9.0%by the close of Mar 26
    Revenue
    $9.23M
    +0.9%
    Net income
    -$5.50M
    N/M
    EPS
    —
    —
  4. Q3 2025Nov 13, 2025, after the closeThe release+2.9%by the close of Nov 14
    Revenue
    $9.49M
    +10.1%
    Net income
    -$3.17M
    N/M
    EPS
    -$0.05
    N/M

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q2 2026Jun 30, 2026Aug 6, 2026 · after-hoursAug 6, 202637 d10-Q$9.63M+0.2%-$0.070.8%
Q1 2026Mar 31, 2026May 13, 2026 · after-hoursMay 13, 202643 d10-Q$8.86M+1.6%-$0.086.0%
FY 2025
Q4 2025derivedDec 31, 2025Mar 25, 2026 · after-hoursMar 30, 202689 d10-K$9.23M+0.9%—9.0%
Q3 2025Sep 30, 2025Nov 13, 2025 · after-hoursNov 13, 202544 d10-Q$9.49M+10.1%-$0.05+2.9%
Q2 2025Jun 30, 2025—Aug 7, 202538 d10-Q$9.62M+8.8%$0.03+4.6%
Q1 2025Mar 31, 2025May 14, 2025 · after-hoursMay 14, 202544 d10-Q$8.73M−2.9%-$0.026.2%
FY 2024
Q4 2024derivedDec 31, 2024Mar 20, 2025 · after-hoursMar 31, 202590 d10-K$9.15M+5.6%—7.8%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q$8.61M−2.2%-$0.0519.3%
Q2 2024Jun 30, 2024Aug 13, 2024 · after-hoursAug 13, 202444 d10-Q$8.84M−6.1%-$0.08+8.9%
Q1 2024Mar 31, 2024May 9, 2024 · after-hoursMay 9, 202439 d10-Q$8.99M−4.9%-$0.11—
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QAug 6, 2026092006
10-QMay 13, 2026060270
10-KMar 30, 2026036451
10-QNov 13, 2025111389
10-QAug 7, 2025001612
10-QMay 14, 2025001268
10-KMar 31, 2025000591
10-QNov 7, 2024001795
10-QAug 13, 2024001368
10-QMay 9, 2024000703

Provenance

ProvenanceData status and checks

Cytosorbents Corp · CIK 1175151 · Engraved from SEC EDGAR